Elexacaftor (VX-445, WHO-11180; WHO11180; VX445; Kaftrio; Trikafta) is one of three components in the fixed-dose combination medication (Elexacaftor/tezacaftor/ivacaftor, trade name: Trikafta and Kaftrio) used in patients who have cystic fibrosis with a F508del mutation. Elexacaftor is a potent and next-generation modulator of cystic fibrosis transmembrane conductance regulator (CFTR) that was designed to restore the function of Phe508del CFTR protein in patients who are diagnnosed with cystic fibrosis. Elexacaftor is administered with tezacaftor and ivacaftor as a three-drug cocktail (Elexacaftor–tezacaftor–ivacaftor).

纯度：≥98%

CAS：2216712-66-0